Dr Walley is Associate Professor of Medicine and an addiction expert at Boston Medical Center and Boston University School of Medicine. Dr Walley has conducted multiple studies related to the opioid crisis and the integration of addiction specialty care and general medical care. He has served as PI on a CDC-SAMHSA-Epi-AID investigation of the surge in fentanyl-related overdose, a CDC-funded study of the Massachusetts OEND program which demonstrated community-level reductions in overdose death rates, and a SAMHSA-funded program that integrated addiction treatment into the clinical care of people with/at risk for HIV. He has worked as Co-I with addiction, overdose, and HIV expertise on NIDA and NIAAA-funded clinical trials and cohort studies.
Dr Walley is the director of the Boston Medical Center Addiction Medicine Fellowship program, as well as the director the NIDA-funded Fellow Immersion Training program in Addiction Medicine, which trains 5 subspecialty fellows each year to integrate addiction science into their subspecialty research. He provides primary care and addiction medicine consultations in the HIV primary care clinic at Boston University School of Medicine/BMC where he leads the FAST PATH (Facilitated Access to Substance abuse Treatment for Prevention and Treatment of HIV) program. Dr Walley co-founded and provides care on the inpatient addiction consult service at Boston Medical Center, which regularly provides consultation for patients admitted to the hospital who use alcohol and substances. Lastly, Dr Walley has been the medical director of the Massachusetts Opioid Overdose Prevention program since it started in 2007. They have trained and equipped over 80,000 people in the community with naloxone rescue kits, culminating in over 19,000 documented overdose rescues.
- Courtesy Staff Privileges, Medicine, Boston Medical Center
- Member, Evans Center for Interdisciplinary Biomedical Research, Boston University
- Faculty, Clinical Addiction Research and Education Unit, Medicine, Boston University School of Medicine
- Johns Hopkins University School of Medicine, MD
- Boston University School of Public Health, MSc
- Harvard College, AB
- Published on 12/8/2020
Komaromy M, Tomanovich M, Taylor JL, Ruiz-Mercado G, Kimmel SD, Bagley SM, Saia KM, Costello E, Park TW, LaBelle C, Weinstein Z, Walley AY. Adaptation of a System of Treatment for Substance Use Disorders During the COVID-19 Pandemic. J Addict Med. 2020 Dec 08. PMID: 33298750.
- Published on 12/1/2020
Morgan JR, Barocas JA, Murphy SM, Epstein RL, Stein MD, Schackman BR, Walley AY, Linas BP. Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting. JAMA Netw Open. 2020 Dec 01; 3(12):e2029676. PMID: 33320266.
- Published on 11/21/2020
Buchheit BM, Crable EL, Lipson SK, Drainoni ML, Walley AY. "Opening the door to somebody who has a chance." - The experiences and perceptions of public safety personnel towards a public restroom overdose prevention alarm system. Int J Drug Policy. 2020 Nov 21; 88:103038. PMID: 33232885.
- Published on 10/29/2020
Gunn CM, Maschke A, Harris M, Schoenberger SF, Sampath S, Walley AY, Bagley SM. Age-based preferences for risk communication in the fentanyl era: 'A lot of people keep seeing other people die and that's not enough for them'. Addiction. 2020 Oct 29. PMID: 33119196.
- Published on 10/4/2020
Winhusen T, Walley A, Fanucchi LC, Hunt T, Lyons M, Lofwall M, Brown JL, Freeman PR, Nunes E, Beers D, Saitz R, Stambaugh L, Oga EA, Herron N, Baker T, Cook CD, Roberts MF, Alford DP, Starrels JL, Chandler RK. The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study. Drug Alcohol Depend. 2020 Dec 01; 217:108325. PMID: 33091842.
- Published on 10/1/2020
Kimmel SD, Walley AY, Li Y, Linas BP, Lodi S, Bernson D, Weiss RD, Samet JH, Larochelle MR. Association of Treatment With Medications for Opioid Use Disorder With Mortality After Hospitalization for Injection Drug Use-Associated Infective Endocarditis. JAMA Netw Open. 2020 10 01; 3(10):e2016228. PMID: 33052402.
- Published on 9/8/2020
Kerensky T, LaRochelle M, Fan SL, Kosakowski S, Wason K, Walley AY. Non-prescription Fentanyl Positive Toxicology: Prevalence, Positive Predictive Value of Fentanyl Immunoassay Screening, and Description of Co-substance Use. J Addict Med. 2020 Sep 08. PMID: 32909981.
- Published on 9/1/2020
Barocas JA, Blackstone E, Bouton TC, Kimmel SD, Caputo A, Porter SJ, Walley AY. Prevalence of Covid-19 Infection and Subsequent Cohorting in a Residential Substance Use Treatment Program in Boston, MA. J Addict Med. 2020 Sep/Oct; 14(5):e261-e263. PMID: 32530889.
- Published on 8/5/2020
Kimmel SD, Kim JH, Kalesan B, Samet JH, Walley AY, Larochelle MR. Against medical advice discharges in injection and non-injection drug use-associated infective endocarditis: A nationwide cohort study. Clin Infect Dis. 2020 Aug 05. PMID: 32756935.
- Published on 7/27/2020
Kimmel SD, Walley AY, Linas BP, Kalesan B, Awtry E, Dobrilovic N, White L, LaRochelle M. Effect of Publicly Reported Aortic Valve Surgery Outcomes on Valve Surgery in Injection Drug- and Non-Injection Drug-Associated Endocarditis. Clin Infect Dis. 2020 Jul 27; 71(3):480-487. PMID: 31598642.
View 136 more publications: View full profile at BUMC